A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

NCT07347171 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
AML
MDS
AML (Acute Myelogenous Leukemia)
MDS (Myelodysplastic Syndrome)

Interventions

DRUG: CG009301 for Injection

Sponsor

Cullgen (Shanghai),Inc